Cytokines in Rheumatoid Arthritis (original) (raw)

• Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 332: 1277–87
  Google Scholar
• Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43: 28–38
  CAS Google Scholar
• Brennan FM, Field M, Chu CQ, et al. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991; 30: 76–80
  PubMed Google Scholar
• Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53
  PubMed CAS Google Scholar
• Firestein GS. The immunopathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1991; 3: 398–406
  PubMed CAS Google Scholar
• Lipsky PE, Davis LS, Cush JJ, et al. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1989; 11: 123–62
  PubMed CAS Google Scholar
• Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Invest Med 1996; 44: 124–35
  CAS Google Scholar
• Szekanecz Z, Halloran MM, Haskell CJ, et al. Mediators of angiogenesis: the role of cellular adhesion molecules. Trends Glycosci Glycotechnol. In press
• Colville-Nash PR, Scott DL. Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51: 919–25
  PubMed CAS Google Scholar
• Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 1995; 7: 229–34
  PubMed CAS Google Scholar
• Canalis E. Regulation in bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Kelseyville: American Society for Bone and Mineral Research, 1990: 23–6
  Google Scholar
• Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305–11
  PubMed CAS Google Scholar
• Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991; 20: 256–72
  PubMed CAS Google Scholar
• Tannenbaum H. Osteopenia in rheumatology practice: pathogenesis and therapy. Semin Arthritis Rheum 1984; 13: 337–48
  PubMed CAS Google Scholar
• Taki H, Sugiyama E, Mino T, et al. Spontaneous production of interleukin-11 and its inhibition by indomethacin and dexamethasone in freshly isolated rheumatoid synoviocytes [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
  Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397–440
  PubMed CAS Google Scholar
• Feldman M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. In: Dixon FJ, editor. Advances in immunology. Vol. 64. London: Academic Press, 1997: 283–350
  Google Scholar
• Barrera P, Boerbooms AMT, van de Putte LBA, et al. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996; 25: 234–53
  PubMed CAS Google Scholar
• Dayer J-M, Arend WP. Cytokines and growth factors. In: Kelle WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 5th ed. Philadelphia: Saunders, 1997: 267–86
  Google Scholar
• Dayer J-M, de Rochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77: 645–8
  PubMed CAS Google Scholar
• McCachren S, Greer PK, Niedel JE. Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritis Rheum 1989; 32: 1539–45
  PubMed CAS Google Scholar
• Leizer T, Clarris BJ, Ash PE, et al. Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum 1987; 30: 562–6
  PubMed CAS Google Scholar
• Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 1988; 106: 311–8
  PubMed CAS Google Scholar
• Goldring MB, Birkheak J, Sandeil LJ, et al. Interleukin 1 suppresses expression of cartilage and specific types I and III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026–37
  PubMed CAS Google Scholar
• Dalton BJ, Connor JR, Johnson WJ. Interleukin-1 induces interleukin-1 alpha and interleukin-1 beta gene expression in synovial fibroblasts and peripheral blood monocytes. Arthritis Rheum 1989; 32: 279–87
  PubMed CAS Google Scholar
• Guerne P-A, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989; 83: 585–92
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Burrows JC, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991; 147: 2187–95
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772–9
  PubMed CAS Google Scholar
• Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410–22
  PubMed Google Scholar
• Abbot SE, Kaul A, Stevens CR, et al. Isolation and culture of synovial microvascular endothelial cells: characterization and assessment of adhesion molecule expression. Arthritis Rheum 1992; 35: 401–6
  PubMed CAS Google Scholar
• Lindsley HB, Smith DD, Davis LS, et al. Regulation of the expression of adhesion molecules by human synoviocytes. Semin Arthritis Rheum 1992; 21: 330–4
  PubMed CAS Google Scholar
• Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1995; 95: 2886–95
  PubMed CAS Google Scholar
• Bismar H, Diel I, Ziegler R, et al. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80: 3351–5
  PubMed CAS Google Scholar
• Horowitz MC. Cytokines and estrogen in bone. Science 1993; 260: 626–8
  PubMed CAS Google Scholar
• Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88–91
  PubMed CAS Google Scholar
• Buchan G, Barrett K, Turner M, et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 1988; 73: 449–55
  PubMed CAS Google Scholar
• Nouri AM, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease: I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295–302
  PubMed CAS Google Scholar
• Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 1986; 65: 293–302
  PubMed CAS Google Scholar
• Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21(10): S447–63
  PubMed CAS Google Scholar
• Dayer J-M, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163–8
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1α: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93: 921–8
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012–8
  PubMed CAS Google Scholar
• Tessier P, Audette M, Cattaruzzi P, et al. Up-regulation by tumour necrosis factor-α of intercellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum 1993; 36: 1528–39
  PubMed CAS Google Scholar
• Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630–2
  PubMed CAS Google Scholar
• Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516–8
  PubMed CAS Google Scholar
• Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041–5
  PubMed CAS Google Scholar
• Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125–32
  PubMed CAS Google Scholar
• Manicourt D-H, Triki R, Fukuda K, et al. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 490–9
  PubMed CAS Google Scholar
• Roubenoff R, Roubenoff RA, Ward LM, et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505–10
  PubMed CAS Google Scholar
• Tetta C, Camussi G, Modena V, et al. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665–7
  PubMed CAS Google Scholar
• Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9: 137–9
  PubMed CAS Google Scholar
• Le J, Vilcrek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588–602
  PubMed CAS Google Scholar
• Motro B, Itin A, Sachs L, et al. Pattern of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A 1990; 87: 3092–6
  PubMed CAS Google Scholar
• Rosen EM, Liu D, Setter E, et al. Interleukin-6 stimulates motility of vascular endothelium. EXS 1991; 59: 194–205
  PubMed CAS Google Scholar
• Houssiau FA, Devogelaer J-P, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–8
  PubMed CAS Google Scholar
• Helle M, Boeije L, de Groot E, et al. Sensitive ELISA for interleukin-6 detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 47–56
  PubMed CAS Google Scholar
• Waage A, Kaufmann C, Espevik T, et al. Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 1989; 50: 394–8
  PubMed CAS Google Scholar
• Madhok R, Crilly A, Murphy E, et al. Gold therapy lowers serum interleukin 6 levels in rheumatoid arthritis. J Rheumatol 1993; 20: 630–3
  PubMed CAS Google Scholar
• Tan PLJ, Farmiloe S, Yeoman S, et al. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 1990; 17: 1608–12
  PubMed CAS Google Scholar
• Field M, Chu C, Feldmann M, et al. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991; 11: 45–50
  PubMed CAS Google Scholar
• Miossec P. Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13Suppl. 12P: S13–6
  PubMed Google Scholar
• van Roon JA, van Roy JL, Gmelig-Meyling FH, et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829–35
  PubMed Google Scholar
• Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 1432–9
  PubMed CAS Google Scholar
• Vannier E, de Waal-Malefyt R, Salazar-Montes A, et al. Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood 1996; 87: 3307–15
  PubMed CAS Google Scholar
• Klareskog L, Ronnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J Intern Med 1995; 238: 191–206
  PubMed CAS Google Scholar
• Sugiyama E, Kuroda A, Taki H, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995; 22: 2020–6
  PubMed CAS Google Scholar
• Koch AE, Fong TW, Volpert OV, et al. Interleukin-4 is an inhibitor of angiogenesis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S304
  Google Scholar
• Bizzarri C, Shioi A, Teitelbaum SL, et al. Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts. J Biol Chem 1994; 269: 13817–24
  PubMed CAS Google Scholar
• Katsikis PD, Chu CQ, Brennan FM, et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517–27
  PubMed CAS Google Scholar
• Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304–10
  PubMed CAS Google Scholar
• Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol 1996; 157: 936–40
  PubMed CAS Google Scholar
• Isomaki P, Luukkainen R, Toivanen P, et al. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1693–702
  PubMed CAS Google Scholar
• Woods JM, Haines GK, Shah MR, et al. Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
  Google Scholar
• Halloran MM, Hosaka S, Woods JM, et al. A new function for interleukin-13 as an endothelial chemotaxin [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
  Google Scholar
• McInnes IB, A1-Mughales J, Field M, et al. The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med 1996; 2: 175–82
  PubMed CAS Google Scholar
• Campbell IK, Waring P, Novak U, et al. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor a. Arthritis Rheum 1993; 36: 790–4
  PubMed CAS Google Scholar
• Pepper MS, Ferrara N, Orci L, et al. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 1995; 108: 73–83
  PubMed CAS Google Scholar
• Waring PM, Carroll GJ, Kandiah DA, et al. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993; 36: 911–5
  PubMed CAS Google Scholar
• Hamilton JA, Waring PM, Filonzi EL. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α. J Immunol 1993; 150: 1496–502
  PubMed CAS Google Scholar
• Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 1993; 91: 1575–81
  PubMed CAS Google Scholar
• Wisniewski HG, Maier R, Lotz M, et al. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993; 151: 6593–601
  PubMed CAS Google Scholar
• Alvaro-Gracia JM, Zvaifler MNJ, Brown CB, et al. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α. J Immunol 1991; 146: 3365–71
  PubMed CAS Google Scholar
• Alvaro-Garcia JM, Zvaifler NJ, Firestein GS. Granulocyte/macrophage colony-stimulating factor–mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989; 170: 865–75
  Google Scholar
• Leizer T, Cebon J, Layton JE, et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990; 76: 1989–96
  PubMed CAS Google Scholar
• Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 191–9
  PubMed CAS Google Scholar
• Sato N, Beitz JG, Kato J, et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142: 1119–30
  PubMed CAS Google Scholar
• Lafyatis R, Remmers EF, Roberts AB, et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. J Clin Invest 1989; 83: 1267–76
  PubMed CAS Google Scholar
• Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149–56
  PubMed CAS Google Scholar
• Klagsbrun M, D’Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217–39
  PubMed CAS Google Scholar
• Sano H, Forough R, Maier JAM, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110: 1417–26
  PubMed CAS Google Scholar
• Goddard DH, Grossman SL, Williams WV, et al. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 1992; 35: 1296–303
  PubMed CAS Google Scholar
• Takeuchi M, Otsuka T, Matsui N, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994; 37: 662–72
  PubMed CAS Google Scholar
• Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63: 265–311
  PubMed CAS Google Scholar
• Wiseman DM, Polverini PJ, Kamp DW, et al. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988; 157: 793–800
  PubMed CAS Google Scholar
• Chu CQ, Field M, Abney E, et al. Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991; 86: 380–6
  PubMed CAS Google Scholar
• Szekanecz Z, Haines GK, Harlow LA, et al. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76: 187–94
  PubMed CAS Google Scholar
• Wahl SM, Allen JB, Wong HL, et al. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 1990; 145: 2514–9
  PubMed CAS Google Scholar
• Gunther M, Haubeck HD, van de Leur E, et al. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum 1994; 37: 395–405
  PubMed CAS Google Scholar
• Wahl SM, Costa GL, Corcoran M, et al. Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553–60
  PubMed CAS Google Scholar
• Fava RA, Olsen NJ, Postlethwaite AE, et al. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med 1991; 173: 1121–32
  PubMed CAS Google Scholar
• Brandes ME, Allen JB, Ogawa Y, et al. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108–13
  PubMed CAS Google Scholar
• Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993; 90: 1937–41
  PubMed CAS Google Scholar
• Koch AE, Halloran MM, Hosaka S, et al. Hepatocyte growth factor: a cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 1996; 39: 1566–75
  PubMed CAS Google Scholar
• Walz A, Kunkel SL, Strieter RM. C-X-C chemokines–an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 1–25
  Google Scholar
• Taub DD. C-C chemokines–an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 27–54
  Google Scholar
• Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996; 58: 6–12
  Google Scholar
• Oppenheim JJ, Zachariae COC, Mukaida N, et al. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Annu Rev Immunol 1991; 9: 617–48
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Strieter RM. Chemokines in arthritis. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 103–16
  Google Scholar
• Peichl P, Ceska M, Effenberger F, et al. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 1991; 34: 333–9
  PubMed CAS Google Scholar
• Rampart M, Herman AG, Grillet B, et al. Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab Invest 1992; 66: 512–8
  PubMed CAS Google Scholar
• Endo H, Akahoshi T, Takagishi K, et al. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res 1991; 10(4): 245–52
  PubMed CAS Google Scholar
• Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798–801
  PubMed CAS Google Scholar
• Hu DE, Hori Y, Fan T-PD. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993; 17: 135–43
  PubMed CAS Google Scholar
• Castor CW, Andrews PC, Swartz RD, et al. The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. Arthritis Rheum 1993; 36: 1142–53
  PubMed CAS Google Scholar
• Bedard PA, Golds EE. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 1993; 154: 433–41
  PubMed CAS Google Scholar
• Koch AE, Kunkel SL, Shah MR, et al. Growth-related gene product alpha: a chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155: 3660–6
  PubMed CAS Google Scholar
• Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992; 149: 722–7
  PubMed CAS Google Scholar
• Hachicha M, Rathanaswami P, Schall TJ, et al. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Arthritis Rheum 1993; 36: 26–34
  PubMed CAS Google Scholar
• Taub DD, Conlon K, Lloyd AR, et al. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-lβ. Science 1993; 260: 355–8
  PubMed CAS Google Scholar
• Akahoshi T, Wada C, Endo H, et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Arthritis Rheum 1993; 36: 762–71
  PubMed CAS Google Scholar
• Fahey III TJ, Tracey KJ, Tekamp-Olson P, et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1991; 148: 2764–9
  Google Scholar
• Koch AE, Kunkel SL, Shah MR, et al. Macrophage inflammatory protein-1 beta: a C-C chemokine in osteoarthritis. Clin Immunol Immunopathol 1995; 77: 307–14
  PubMed CAS Google Scholar
• Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669–71
  PubMed CAS Google Scholar
• Rathanaswami P, Hachicha M, Sadick M, et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. J Biol Chem 1993; 268: 5834–9
  PubMed CAS Google Scholar
• Robinson E, Keystone EC, Schall TJ, et al. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 1995; 101: 398–407
  PubMed CAS Google Scholar
• Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15
  PubMed CAS Google Scholar
• Evans CH, Robbins PD. Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 1996; 8: 230–4
  PubMed CAS Google Scholar
• Nita I, Ghivizzani SC, Galea-Lauri J, et al. Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820–8
  PubMed CAS Google Scholar
• Kingsley G, Panayi G, Lanchbury J. Immunotherapy of rheumatic diseases–practice and prospects. Immunol Today 1991; 12: 177–9
  PubMed CAS Google Scholar
• Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996; 8: 195–200
  PubMed CAS Google Scholar
• Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42
  PubMed CAS Google Scholar
• Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082–91
  PubMed CAS Google Scholar
• Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077–81
  PubMed CAS Google Scholar
• Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62
  PubMed CAS Google Scholar
• Kyle V, Coughlan RJ, Tighe H. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428–9
  PubMed CAS Google Scholar
• Harris Jr ED. Treatment of rheumatoid arthritis. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1996: 912–23
  Google Scholar
• American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22
  Google Scholar
• Goodwin JS. Nonsteroidal antiinflammatory drugs. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1959–67
  Google Scholar
• Cash JM, Hoffman GS. Glucocorticoids. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1947–58
  Google Scholar
• Cash JM, Hoffman GS. Immunomodulatory pharmaceuticals. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1980–92
  Google Scholar
• Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244–52
  PubMed CAS Google Scholar
• Danis VA, Franic GM, Rathjen DA, et al. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis 1992; 51: 946–50
  PubMed CAS Google Scholar
• Dougados M. Cyclosporin in rheumatoid arthritis. Clin Exp Rheumatol 1994; 12Suppl. 11: S75–8
  PubMed Google Scholar
• Fagrinoli S, van Thiel DH. Immunophillin binding agents. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1993–2001
  Google Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40–5
  PubMed CAS Google Scholar
• Fauci AS, Young Jr KR. Immunomodulatory agents. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1996: 797–821
  Google Scholar
• Girasole G, Jilka RL, Passed G, et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89: 883–91
  PubMed CAS Google Scholar
• Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499–505
  PubMed CAS Google Scholar
• Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125 Suppl.: 1704S–8S
  PubMed CAS Google Scholar
• Lacey DL, Erdmann JM, Tan HL, et al. Murine osteoblast interleukin 4 receptor expression: upregulation by 1,25 dihydroxyvitamin D3. J Cell Biochem 1993; 53: 122–34
  PubMed CAS Google Scholar
• Pennanen N, Lapinjoki S, Urtti A, et al. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916–22
  PubMed CAS Google Scholar
• Choy EHS. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 1998; 12: 139–48
  PubMed CAS Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31
  PubMed CAS Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784–8
  PubMed CAS Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993; 36: 1681–90
  PubMed CAS Google Scholar
• Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; I: 244–7
  Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fusion protein. N Engl J Med 1997; 337: 141–97
  PubMed CAS Google Scholar
• Drevlow BE, Lovis R, Hang R, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39: 257–65
  PubMed CAS Google Scholar
• Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987; 139: 1546–9
  PubMed CAS Google Scholar
• Carter DB, Deibel Jr MR, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633–8
  PubMed CAS Google Scholar
• Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993; 36: 781–9
  PubMed CAS Google Scholar
• Krzesicki RF, Hatfield CA, Bienkowski MJ, et al. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 1993; 150: 4008–18
  PubMed CAS Google Scholar
• Lebsack ME, Paul CC, Bloedow DC. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991; 34 Suppl.: S45
  Google Scholar
• Chole RA, Faddis BT, Tinling SP. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist. J Bone Miner Res 1995; 10: 281–4
  PubMed CAS Google Scholar
• Chernajovsky Y, Annenkov A, Herman C, et al. Gene therapy for rheumatoid arthritis: theoretical considerations. Drugs Aging 1998; 12: 29–41
  PubMed CAS Google Scholar
• Raz E, Watanabe A, Baird SM, et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A 1993; 90: 4523–7
  PubMed CAS Google Scholar
• Koch AE, Kurata H, Hosaka S, et al. Use of the rat adjuvant-induced arthritis as a model for rheumatoid arthritis gene therapy [abstract]. Arthritis Rheum 1996; 39 Suppl.: S248
  Google Scholar